Effects of Trimetazidine combined with Clopidogrel in treatment of patients with coronary heart disease and angina pectoris
Objective:To observe effects of Trimetazidine combined with Clopidogrel in treatment of patients with coronary heart disease and angina pectoris.Methods:A prospective study was conducted on 100 patients with coronary heart disease and angina pectoris admitted to this hospital from January 2020 to January 2023.According to the random number table method,they were divided into study group and control group,50 cases in each group.The control group was treated with Clopidogrel,while the study group was treated with Trimetazidine hydrochloride on the basis of that of the control group.The clinical efficacy,the levels of angina pectoris attack indexes(duration of angina pectoris attack and frequency of angina pectoris attack),cardiac function indexes[left ventricular ejection fraction(LVEF),left ventricular end-systolic diameter(LVESD),left ventricular end-diastolic diameter(LVEDD)]and myocardial injury markers[creatine kinase isoenzyme(CK-MB),growth differentiation factor-15(GDF-15),copeptin(CPP),N-terminal pro-brain natriuretic peptide(NT-proBNP)],and the incidence of adverse reactions were compared between the two groups.Results:The total effective rate of treatment in the study group was 96.00%(48/50),which was higher than 84.00%(42/50)in the control group,and the difference was statistically significant(P<0.05).After the treatment,the duration of angina pectoris in the two groups was shorter than that before the treatment,and that in the study group was shorter than the control group;the frequencies of angina pectoris attacks in the two groups were less than those before the treatment,and that in the study group was less than that in the control group;and the differences were statistically significant(P<0.05).After the treatment,the LVEF levels of the two groups were higher than those before the treatment,and that in the study group was higher than that in the control group;the levels of LVESD and LVEDD in the two groups were lower than those before the treatment,and those in the study group were lower than those in the control group;and the differences were statistically significant(P<0.05).After the treatment,the levels of CPP,GDF-15,CK-MB and NT-proBNP in the two groups were lower than those before the treatment,those in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Trimetazidine combined with Clopidogrel in the treatment of the patients with coronary heart disease and angina pectoris can improve the total effective rate of treatment,improve the levels of cardiac function indexes,and reduce the levels of myocardial injury markers and angina pectoris indexes.Moreover,it is superior to single Clopidogrel treatment.
TrimetazidineClopidogrelCoronary heart disease and angina pectorisCardiac functionMyocardial injuryAngina attackAdverse reaction
NETL
NSTL
万方数据
